Ultra-high resolution PET brain scans for aging, dementia, and psychosis
Part of Brain & nervous system, Eyes & vision, Heart & circulation, Hormones & metabolism, Mental health clinical trials.
This study uses a new ultra-high resolution PET scanner to look at brain changes in healthy aging, dementia, ALS, movement disorders, and psychosis. It aims to better understand these conditions and improve imaging techniques.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 90 years old.
- For healthy volunteers: no major medical, neurological, or psychiatric conditions, and no memory problems.
- For patients: have a specific diagnosis like dementia, Parkinson's, ALS, or psychosis.
- You must be able to lie still in a scanner for about an hour.
- No past or current drug or alcohol abuse.
- No metal implants or other reasons you can't have an MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a new radioactive tracer called [18F]-MFBG can help doctors better distinguish between Parkinson's disease, multiple system atrophy (MSA), dementia with Lewy bodies, and Alzheimer's disease. It compares the new scan with two standard scans to see which is most accurate.
This study compares a newer PET/CT scanner (called NeuroEXPLORER) with standard PET/CT scanners for imaging the head and neck region. The goal is to see if the new scanner provides better or clearer images to help diagnose conditions.
This trial uses a new imaging agent (like a dye) to see signs of Parkinson's disease in the brain. If you have Parkinson's or a related condition like Lewy body dementia or multiple system atrophy, this scan may help researchers better understand these illnesses.
This study uses special brain scans to measure proteins and connections in the brain after a recent injury, stroke, or in people with mild memory/behavior changes. The goal is to understand brain changes and how they relate to symptoms, which may help future diagnosis and treatment.
This trial uses a new type of PET scan to look for specific proteins in the brain that are linked to Alzheimer's disease. It will help doctors see how these proteins relate to cognitive decline and compare scans from people with normal thinking to those with memory problems.
This early-phase study tests a new PET scan tracer that targets a brain chemical transport system involved in dementia. It aims to see if the tracer can safely and clearly show brain changes, which could help future dementia diagnosis or tracking.
Hear when a new Alzheimer Dementia (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.